IP Library › Granted Patent US 10,188,682
Granted Patent B2
US 10,188,682 · App. 14/875,879 · Granted Jan 29, 2019

Medicament for liver regeneration and for treatment of liver failure

Inventors: Lars Zender (Braunschweig, DE); Torsten Wuestefeld (Braunschweig, DE)
Assignees: HELMHOLTZ-ZENTRUM FÜR INFEKTIONSFORSCHUNG GMBH; MEDIZINISCHE HOCHSCHULE HANNOVER
A61K35/407A61K31/00A61K31/352A61K31/353A61K31/416A61K31/4709A61K31/519A61K31/52A61K31/53A61K31/5377A61K31/713A61M1/02C07C237/42C07D213/75C07D231/54C07D231/56C07D311/30C07D311/36C07D401/12C07D407/12C07D473/38C07D487/04C12M3/00C12N5/067C12N15/1137C12Y207/11024C12N2310/14C12N2310/141C12N2310/531
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,188,682
App. No.
14/875,879
Granted
Jan 29, 2019
Kind
B2
Abstract

The present invention relates to the use of a compound which inhibits the activity of MKK4 as a medicament for the treatment of a patient suffering from an impaired liver function, to the use of a compound as a medicament for the treatment of liver failure, including acute/fulminant or chronic liver failure and/or for increasing the regeneration of liver tissue in a patient.

Claims (4)

1. A method of treatment of liver failure and/or for the protection of hepatocytes against apoptosis and/or for the regeneration of hepatocytes, the method comprising a step of administering to a patient in need of treatment a compound, which is an inhibitor of the activity of MKK4, MKK4 being encoded by the mRNA of SEQ ID NO: 1204, wherein the compound is selected from the group consisting of the following compounds:

2. The method according to claim 1 , wherein the compound is formulated as liposomes or lipid nanoparticles.

3. The method according to claim 1 , wherein the compound is a compound having the following structure:

4. The method according to claim 1 , wherein the patient is a human patient.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 29, 2017
From: ZENDER, LARS; WUSTEFELD, TORSTEN
To: HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH; MEDIZINISCHE HOCHSCHULE HANNOVER
Reel/Frame 044249/0220 →
Priority Claims (2)
EP 11161588 · Apr 7, 2011 · regional
EP 11167373 · May 24, 2011 · regional
Continuity (3)
Continuation 14009738
Provisional Application 61473015 · Apr 7, 2011
Related Publication 20160022742A1 · Jan 28, 2016